



AEROSPACE
& DEFENSE



AUTOMOTIVE



LIFE
SCIENCES



GENERAL
INDUSTRIAL



ELECTRICAL

Lake Street Investor Conference

Sept 13th



Forward looking statements


Forward Looking Statements: With the exception of the historical information contained in this presentation, the matters described herein contain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained herein include, but are not limited to, information regarding the ability of NN, Inc. (“NN”) and Paragon Medical, Inc. (“Paragon”) to complete the transactions contemplated by the Stock Purchase Agreement, dated April 2, 2018, including the satisfaction of conditions to the transactions set forth in the Stock Purchase Agreement, and NN’s and the combined entity’s estimated or anticipated future results of operations. These forward-looking statements involve risks and uncertainties that could cause NN’s and the combined entity’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, general economic conditions and economic conditions in the industrial sector, competitive influences, risks that current customers of NN or Paragon will commence or increase captive production, delayed customer product launches, risks of capacity underutilization, quality issues, availability of raw materials, currency, pending and complete transactions and other risks associated with international trade, the Company’s dependence on certain major customers, unforeseen changes in future revenues, earnings and profitability of NN or Paragon, the risk that NN is not able to realize the savings or benefits expected from integration and restructuring activities related to the proposed acquisition of Paragon, the risk that the required regulatory approvals for the proposed acquisition of NN are not obtained, are delayed or are subject to conditions that are not anticipated, and those risks and uncertainties discussed in NN’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 2, 2018.

This presentation contains certain forward looking non-GAAP financial measures, estimated 2018 adjusted earnings before interest, taxes and depreciation and estimated 2018 adjusted operating margin, which cannot be reconciled without unreasonable effort. The following forward looking financial measures regarding Paragon is unavailable to NN: (i) depreciation and amortization; (ii) income taxes; and (iii) net income, and this information could have a material impact on these certain forward looking non-GAAP financial measures.

Disclaimer: NN disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements included herein or therein to reflect future events or developments. The information contained in this presentation is submitted on a confidential basis solely for the recipient’s use and the recipient agrees to maintain the confidentiality of the information contained herein and not to reproduce or distribute any confidential information contained herein to any third party without our express written authorization.




Strategic Plan at a Glance





NN, Inc. Timeline of Strategic Events

NN has taken many strategic actions in the last several years to enhance Company growth



■ Denotes significant event

Source: Company press releases



Impressive Historical Financial Performance




¹ Please see appendix for reconciliation

We expect current operating model and recent strategic initiatives to offer strong future growth opportunities



Diversified Portfolio with Secular Trends






Paragon Medical Acquisition Overview


Global Centers of Excellence

Over 350,000 sqft Manufacturing Space
~1,300 Employees



Integrated, End-to-End Solutions

Single source Partner from design to commercial production



Full Suite of Product Applications

Product applications across all orthopaedic segments (e.g., large joints, trauma, extremities)



Implantable
Components
23% of Sales




Custom Delivery
Systems
33% of Sales




Surgical
Instrumentation
44% of Sales


1991 – 2005 Define Vision & Develop Operations



2006 – 2014 Facility Investment & Expansion






2015 – Present Global Platform for Growth






Comprehensive Product Portfolio – Life Sciences

			Combined Life Sciences Portfolio
Finished Devices			
Orthopedics			
Surgical Tools			
Spine			
Extremity			
Endoscopic			
Drug Delivery			
Delivery Systems			





Balanced Portfolio




- \$860M of estimated revenue moves us closer to strategic target of \$1B
- Post transaction cyclical automotive exposure reduced to ~5%
- Fills strategic EBITDA gap left by PBC divestiture
- Balances economic cyclicality
- Enhances path to long term sustainability
- Accretive to margin and earnings profile day 1
- Improves capital intensity profile



A Diversified Industrial Business

End Markets as a % of Revenue


Pre-Paragon - 2017



56% Diverse Portfolio

End Markets as a % of Revenue¹


2018^E



66% Diverse Portfolio

End Markets as a % of EBITDA


Pre-Paragon - 2017



61% Diverse Portfolio

End Markets as a % of EBITDA¹


2018^E



70% Diverse Portfolio

End Markets as a % of Free Cash Flow


Pre-Paragon - 2017



67% Diverse Portfolio

End Markets as a % of Free Cash Flow¹

2018^E



77% Diverse Portfolio

Automotive

Electrical

General Industrial

Aerospace & Defense


CAFE Technology

Medical


^E Estimated; ¹ Based on 2018 full year guidance, assumes Bridgemedica & Paragon acquisitions occurred 1-1-18




Strategic Global Footprint




**Pre-Paragon 2018^E
Geographic Revenue Mix***



**Paragon 2018^E
Geographic Revenue Mix**



**Combined Business 2018^E
Geographic Revenue Mix***



51 Facilities Worldwide

E - Estimated

*Based on 2018 full year guidance, assumes Bridgemedica & Paragon acquisitions occurred 1-1-18

www.nninc.com



Balanced Customer Base

Johnson & Johnson  **BOSCH**

 ZIMMER BIOMET

stryker[®]  **Medtronic**

Itron

DENSO



Copeland[®]
brand products




TRW

- More balanced customer mix
- 3 new Life Sciences customers enter top 10
- No Customer greater than 8%
- Balance early and late cycle of the portfolio
- Blue Chip customer base in every market




Updated Strategic Targets





Strategy Remains Unchanged





3rd Quarter 2018 Guidance

	2 nd Quarter 2018 Actual	3 rd Quarter 2018 Guidance	
Net Sales	\$196.3M	\$210M-\$215M	Reflects a full quarter of Paragon acquisition
Adjusted Operating Margin^(a)	12.6%	12.5% - 13.0%	Margin expansion from flex productivity on incremental sales volume and inclusion of acquisitions
Adjusted EBITDA	\$36.3M	\$40M - \$42M	Reflects a full quarter of Paragon acquisition
Adjusted Diluted EPS^(b)	\$0.38	\$0.38- \$0.43	



2018 Full Year Guidance

	Revised Guidance	Commentary
Net Sales	\$775M-\$800M	Markets performing as expected
Adjusted Operating Margin^(a)	12.5%-13.0%	Margin expansion reflecting flex productivity and acquired business performance
Adjusted EBITDA	\$143M-\$150M	
Adjusted Diluted EPS^(b)	\$1.60-\$1.75	Revised tax on foreign earnings impact of \$0.08 - \$0.10
CAPEX	\$45M-\$53M	Inclusive of acquisitions
Free Cash Flow¹	\$40M-\$46M	Performance continues to improve

Engineered Solutions



AEROSPACE
& DEFENSE



AUTOMOTIVE



MEDICAL



GENERAL
INDUSTRY



ELECTRICAL

Inspired by iNNovation